Biovie INC 10-Q quarterly reports

BioVie Inc. reported a net loss of $5.3 million for the third quarter of fiscal year 2026, an increase from $2.8 million in the prior year, driven by higher research and development expenses for ongoing clinical trials.

BioVie Inc. reported a reduced net loss in its second fiscal quarter, driven by lower operating expenses, while advancing its Parkinson's and Long COVID clinical programs and preparing for a potential liver disease spin-off.

BioVie Inc. reported an increased net loss for Q1 2026, raised $10.5 million in a public offering, and disclosed significant protocol violations in its Alzheimer's Phase 3 trial.

BioVie Inc. announces its financial results for the quarter ended March 31, 2025, and provides updates on its clinical development programs for neurodegenerative and liver diseases.

BioVie Inc. announces its financial results for the quarter ended December 31, 2024, and provides updates on its clinical development programs for neurodegenerative and liver diseases.

BioVie Inc. announced its financial results for the first quarter of fiscal year 2025, ended September 30, 2024, and provided updates on its clinical development programs.

BioVie Inc. released its unaudited financial results for the third quarter of 2024, detailing progress in its clinical programs and financial position.

BioVie Inc. reports a reduced net loss for the second quarter of 2024 compared to the same period last year, while also providing updates on its clinical programs for Alzheimer's and liver disease.